- AstraZeneca announced positive results from its clinical trial for its metastatic non-small cell lung cancer drug, which had 'significantly improved survival rates.

Tagrisso showed a statistically-significant and clinically-meaningful improvement in overall survival, a secondary endpoint in the FLAURA Phase III trial, compared with erlotinib or gefitinib both of which were previous standard-of-care treatments in this setting, the company said.

The Flaura trial met its primary endpoint in July 2017, showing a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS), increasing the time patients lived without disease progression or death from any cause.

'Today's positive results show that Tagrisso provides an unprecedented survival outcome versus previous standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors, reaffirming Tagrisso as the 1st-line standard-of-care for EGFR-mutated metastatic non-small cell lung cancer,' said José Baselga, Executive Vice President, Oncology R&D.

Story provided by